34D Stock Overview
Engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
DiaSorin S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €103.85 |
| 52 Week High | €105.35 |
| 52 Week Low | €80.98 |
| Beta | 0.16 |
| 11 Month Change | 1.42% |
| 3 Month Change | 11.40% |
| 1 Year Change | 22.78% |
| 33 Year Change | -41.93% |
| 5 Year Change | 0.44% |
| Change since IPO | 738.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 34D | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 3.6% | 1.5% |
| 1Y | 22.8% | 3.6% | 12.6% |
Return vs Industry: 34D exceeded the German Medical Equipment industry which returned 3.6% over the past year.
Return vs Market: 34D exceeded the German Market which returned 12.6% over the past year.
Price Volatility
| 34D volatility | |
|---|---|
| 34D Average Weekly Movement | 3.4% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 34D has not had significant price volatility in the past 3 months.
Volatility Over Time: 34D's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,186 | Carlo Rosa | diasoringroup.com/en |
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System.
DiaSorin S.p.A. Fundamentals Summary
| 34D fundamental statistics | |
|---|---|
| Market cap | €5.48b |
| Earnings (TTM) | €167.74m |
| Revenue (TTM) | €1.16b |
32.6x
P/E Ratio4.7x
P/S RatioIs 34D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 34D income statement (TTM) | |
|---|---|
| Revenue | €1.16b |
| Cost of Revenue | €408.59m |
| Gross Profit | €752.43m |
| Other Expenses | €584.70m |
| Earnings | €167.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 05, 2024
| Earnings per share (EPS) | 3.15 |
| Gross Margin | 64.81% |
| Net Profit Margin | 14.45% |
| Debt/Equity Ratio | 59.1% |
How did 34D perform over the long term?
See historical performance and comparison